Skip to content

To Develop, Implement and Evaluate the Polio Demonstration Project Comprising of a Community Based Intervention Package for Polio Eradication in Pakistan

To Develop, Implement and Evaluate the Polio Demonstration Project Comprising of a Community Based Intervention Package for Polio Eradication in Pakistan

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01908114
Enrollment
60000
Registered
2013-07-25
Start date
2013-07-31
Completion date
2021-12-31
Last updated
2021-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunization Coverage, Polio, Polio Sero Conversion, Polio Sero Prevalence

Keywords

Polio disease, Intervention Package, Polio sero prevalence and sero conversion, Polio high risk areas of Pakistan

Brief summary

The objective of the projects is to Develop and implement a Package of interventions that will comprise of an augmented communication and counseling strategy coupled with private sector involvement and a combined Oral Polio Vaccine and Inject able Polio Vaccine approach during the Polio campaigns followed by the evaluation of this project for acceptability, feasibility and effectiveness of the intervention Package.

Detailed description

This particular project has been designed to address the bottlenecks through innovations to address community mobilization and demand creation on one hand and assess the synergistic immune enhancement potential of combining Inject able Polio Vaccine (IPV) and Oral Polio Vaccine (OPV) in at-risk children. This project will be implemented in high risk union councils of Karachi, district Kashmore in Sindh and Bajaur Agency in Federally administered Tribal areas (FATA) This will be a three cell cluster randomized trial to achieve the objectives of the study. The first cell of the study will receive all the routine activities being carried out by the polio program, the second cell will receive an expanded intervention with community support groups, enhanced communication package, education and counseling and involvement of private sector. While the third cell will receive all of the interventions of second cell with a combined OPV IPV approach during the polio immunization campaign through child health camps. We have calculated a total sample size of 120 clusters, 40 clusters per group for each study area i-e 120 for Karachi, 120 for Kashmore and 120 for Bajaur. Polio program in Pakistan has well established and demarcated vaccination areas assigned to a vaccination team, each vaccination area usually covers about 200 children therefore the area of vaccination team will be considered as one cluster in the proposed study. The implementation of the project will be followed by impact assessment activities that will include post vaccination coverage surveys and Immunity assessment activities and Environmental sample collection. A total sample size of 5310 children has been calculated for the immunity studies for seroprevalance and 5130 for stool virus shedding

Interventions

BEHAVIORALEnhanced Community mobilization
BIOLOGICALCombined Oral Polio Vaccine and Inject able Polio Vaccine during SIA

Sponsors

Pakistan Ministry of Health
CollaboratorOTHER_GOV
Trust for Vaccines and Immunization, Pakistan
CollaboratorOTHER
National Institutes of Health, Pakistan
CollaboratorOTHER
Peshawar Medical College
CollaboratorOTHER
World Health Organization
CollaboratorOTHER
UNICEF
CollaboratorOTHER
Bill and Melinda Gates Foundation
CollaboratorOTHER
Aga Khan University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Months to 5 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy children aged 1 month to 5 years that reside within the study sites, and do not plan to travel away during entire the study period.

Exclusion criteria

* Children with known thrombocytopenia or bleeding disorders; children acutely ill or with signs of acute infection (e.g. fever ≥ 101 F) at the time of NID and a diagnosis or suspicion of immunodeficiency disorder.

Design outcomes

Primary

MeasureTime frameDescription
Improved immunization coverageAt the completion of all recruitment and follow ups which will take an average time of 1 yearImproved coverage in both routine immunization and polio campaign Immunization compared to Baseline

Secondary

MeasureTime frameDescription
Improved Polio Sero prevalenceThe immunity levels will be assessed at the time of recruitment, six weeks after recruitment and 18 weeks after recruitmentPopulation bases Immunity level for polio antibodies will be assessed by Sero prevalance and conversion at various time points
Quantification of Polio virus in stool samplesThe stool samples will be collected and analysed at day 28, day 35 and day 49 after recruitmentQuantification of Polio virus will be assessed in stool samples collected at day 28, day 35 and day 49 after recruitment
Shedding of Polio virus in stool samplesThe stool samples will be collected and analysed at day 28, day 35 and day 49 after recruitmentShedding of Polio virus in stool samples will be assessed at day day 28, day 35 and day 49 after recruitment

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026